Commercial cGMP production elevates lab radiolabeling into validated, compliant manufacturing for consistent high-volume radiopharmaceuticals for global trials and commercial use. As a dedicated Radiopharmaceutical CRDMO and CRO, Protheragen delivers comprehensive Commercial Scale cGMP Production Services that span facility design, multi-nuclide manufacturing line establishment, technology transfer, process validation, and regulatory-compliant batch release, providing sponsors with the infrastructure, expertise, and quality systems necessary to advance from clinical development through commercial supply with confidence and efficiency.
Commercial-scale cGMP production of radiopharmaceuticals represents a highly specialized manufacturing discipline that bridges nuclear chemistry, pharmaceutical engineering, and radiation safety within a framework of stringent regulatory compliance. Unlike conventional pharmaceutical manufacturing, radiopharmaceutical production must accommodate the unique challenges of radioactive materials—including short half-lives that mandate just-in-time synthesis, radiation shielding requirements that dictate facility design, and the inherent instability of radioactive compounds that necessitates rapid quality control and release procedures. cGMP facilities for radiopharmaceuticals are designed with lead or tungsten-shielded hot cells for radiolabeling and dispensing, automated synthesis modules that minimize human exposure, aseptic processing environments that meet Grade A/Grade B cleanroom standards, and dedicated quality control laboratories equipped with radioanalytical instrumentation such as gamma spectrometers, radio-HPLC systems, and radio-TLC scanners.
Fig 1. Summary of approved radiopharmaceuticals. (Zhang, Siqi, et al., 2025)
The transition from clinical-scale to commercial-scale production involves a systematic scale-up process that includes technology transfer from development laboratories to manufacturing suites, process validation to demonstrate reproducibility across multiple batches, analytical method validation to ensure quality control reliability, and stability studies to establish shelf-life specifications. For multi-nuclide facilities, the challenge is compounded by the need to accommodate diverse isotope half-lives, decay characteristics, and shielding requirements within a single manufacturing infrastructure. Commercial production also demands robust supply chain management for isotope procurement, precursor sourcing, and waste disposal, as well as contingency planning for equipment failures, isotope shortages, or demand surges. Successful commercial-scale cGMP production requires not only technical and operational excellence but also a deep understanding of regulatory expectations, risk management principles, and the economic drivers of radiopharmaceutical commercialization.
Protheragen delivers comprehensive Commercial Scale cGMP Production Services specifically engineered for the radiopharmaceutical industry, integrating state-of-the-art manufacturing facilities, multi-nuclide production capabilities, seamless technology transfer, rigorous process and analytical validation, and ICH-compliant stability programs to ensure that every batch meets the highest standards of quality, safety, and regulatory compliance. Our integrated CRDMO and CRO platform provides sponsors with the flexibility to scale from clinical trial supply through full commercial manufacturing, leveraging dedicated, shared, or customized production lines tailored to their specific product requirements and market demands.
Protheragen's cGMP facilities comply GMP standards, equipped with shielded hot cells, aseptic zones and full QC instruments. Licensed for over 30 radionuclides, it supports batches from single-patient doses to commercial volumes.
Our modular GMP lines rapidly switch between alpha, beta and positron emitters via interchangeable cassettes and adjustable shielding. It cuts downtime, boosts facility utilization and includes full isotope supply chain support.
We deliver structured tech transfer of radiopharmaceutical synthesis from labs to cGMP plants, covering gap analysis, equipment qualification, process optimization and complete regulatory docs for IND/CTA filings.
Cost-efficient campaign-based shared GMP suites eliminate facility construction costs for mid-stage radiopharmaceutical projects. Strict cleaning validation avoids cross-contamination, suitable for Phase II–III trials and low-volume commercial drugs.
Hybrid production lines combine shared infrastructure with client-specific synthesis modules, custom shielding and exclusive QC assays. Balances dedicated manufacturing performance with low capital costs for clinical and early commercial stages.
Exclusive single-product manufacturing suites for high-volume radiopharmaceuticals. Featuring independent equipment, QC labs and fixed teams, it removes cross-contamination risks and grants full schedule & supply control to sponsors.
We perform full radiopharmaceutical process validation based on QbD and DoE to confirm consistent product quality. Services include media fills, three validation batches and continuous monitoring tailored to short-lived radionuclides.
Regulatory-compliant analytical method validation under ICH Q2(R1) for radiopharmaceutical release testing, covering radio-HPLC, radio-TLC, gamma spectrometry and residual solvent detection with complete validation data packages.
ICH-aligned real-time and accelerated stability testing to define radiopharmaceutical shelf life and storage rules. Custom timelines for short/long half-life radionuclides, testing purity, molar activity and other key quality indicators for regulatory submissions.
Protheragen's Commercial Scale cGMP Production Services follow a structured, phase-gated workflow designed to ensure that every radiopharmaceutical product transitions smoothly from development through commercial manufacturing with full regulatory compliance, consistent quality, and operational efficiency. Our integrated approach coordinates facility engineering, process development, quality systems, and regulatory strategy to deliver robust, audit-ready manufacturing outcomes.
Whether you are scaling a novel radiopharmaceutical from clinical development to commercial production, seeking a flexible multi-nuclide manufacturing partner, or requiring dedicated cGMP capacity for a high-volume therapeutic product, Protheragen is ready to support your program with the manufacturing expertise, regulatory compliance, and production infrastructure it demands. Reach out to us today to discuss how our Commercial Scale cGMP Production Services can accelerate your path from development to global market supply. Contact our manufacturing strategy team to schedule a consultation and explore a tailored partnership approach.
Reference